Heidi Splete
News
Intervention improves antibiotics use in UTIs
March 3, 2020
To promote judicious antibiotic use, researchers designed an intervention including the development of new local UTI guidelines and a live, case-based educational session.
News
Antibiotic resistance rises among pneumococcus strains in kids
March 1, 2020
Evolution is at work in the emergence of vaccine-resistance serotypes not included in the PCV-13 vaccine.
News
Vitamin E acetate found in more vapers’ lung fluid
February 22, 2020
Researchers identified vitamin E acetate in the bronchoalveolar-lavage fluid of additional patients with electronic-cigarette, or vaping, product use–associated lung injury.
![1]()
News
Infection with 2019 novel coronavirus extends to infants
February 18, 2020
Nine infants with at least one infected family member have tested positive for the 2019 novel coronavirus.
News
Initial ultrasound assessment of appendicitis curbs costs
February 2, 2020
Patients at low to medium risk for appendicitis can benefit from initial ultrasound to assess need for further action.
![1]()
News
EVALI update warns of chemicals in vaping products
January 24, 2020
Data from the Centers for Disease Control and Prevention show 82% of EVALI patients reported using a vaping product containing THC.
News
Vitamin E acetate confirmed as likely source of EVALI
December 23, 2019
Most patients with vaping-associated lung problems reported THC or nicotine vaping within 90 days of illness onset.
News
Short-term statin use linked to risk of skin and soft tissue infections
October 11, 2019
Use of statins was associated with increased risk of SSTIs at an average of 91, 182, and 365 days.
![1]()
News
Clinician burnout can impact quality of care
October 7, 2019
A meta-analysis suggests that burnout may be associated with lower quality of care, but the effect may be less because of study limitations.
News
Lefamulin found noninferior to moxifloxacin for bacterial pneumonia
October 1, 2019
Oral lefamulin, the first pleuromutilin antibiotic approved for intravenous and oral administration, was noninferior to oral moxifloxacin for inducing an early clinical response in patients with bacterial pneumonia, acording to data from a global multicenter study of 738 individuals.
